CSIMarket Company Name, Ticker, Competitors, else..
 

Keenova Therapeutics Plc  (MNK)

Keenova Therapeutics Plc's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

MNK Sales vs. its Competitors Q1 2026


Comparing the current results to its competitors, Keenova Therapeutics Plc reported Revenue increase in the 1 quarter 2026 by 11.36 % year on year.
The revenue growth was below Keenova Therapeutics Plc's competitors' average revenue growth of 27.91 %, achieved in the same quarter.

• List of MNK Competitors





Revenue Growth Comparisons




Net Income Comparison

Keenova Therapeutics Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 27.04 %

<<  MNK Stock Performance Comparisons


Keenova Therapeutics Plc's Comment on Competition and Industry Peers


The company faces competitive challenges including potential loss of contracts with Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs), which may result in decreased net sales. Distributors are forming strategic alliances and engaging in more aggressive negotiations, potentially leading to reduced market share or lower pricing. Outside the United States, pricing pressure stems from centralized governmental healthcare authorities and competitive bidding processes. Regulatory requirements and possible delays in product approvals also affect the company's competitive position. The company depends significantly on a limited number of independent wholesale distributors, large pharmacy chains, and specialty distributors, which could negatively impact business if sales volumes decline.



  

Overall company Market Share Q1 2026
Overall company revenue, increased less, than total company revenues, at 11.36 % and lost market share, to approximately 0.79 %.
<<  More on MNK Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Keenova Therapeutics Plc




Beyond Air Inc
Share Performance



-42.18%
30 Days
Beyond Air Inc
Profile

Beyond Air Inc is a company that operates on a business model focused on developing and commercializing medical devices for the treatment of respiratory conditions using innovative nitric oxide technology.

More about Beyond Air Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 26.401 mill. $ 6.677 mill. $ -34.410 mill.


Ironwood Pharmaceuticals inc
Share Performance



-2.63%
Over The Past 5 Days
Ironwood Pharmaceuticals inc
Profile

Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.

More about Ironwood Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 712.516 mill. $ 361.514 mill. $ 102.176 mill.


Immuron Limited
Share Performance



0.00%
30 Days
Immuron Limited
Profile

Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.

More about Immuron Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 6.765 mill. $ -5.216 mill.


Galmed Pharmaceuticals Ltd
Share Performance



+426.53%
This Quarter
Galmed Pharmaceuticals Ltd
Profile

Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.

More about Galmed Pharmaceuticals Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.139 mill. $ - mill. $ 1.400 mill.


Diamedica Therapeutics Inc
Share Performance



+4.75%
This Quarter
Diamedica Therapeutics Inc
Profile

Diamedica Therapeutics Inc's business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.

More about Diamedica Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 344.385 mill. $ - mill. $ -37.541 mill.

46 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Keenova Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Keenova Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.